tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mouth Diseases D009059 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Hallucinations D006212 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Viremia D014766 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gout D006073 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Parotitis D010309 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Impetigo D007169 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Anus Diseases D001004 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Scleritis D015423 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Legionellosis D007876 3 associated lipids
Pityriasis D010915 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cavaillé-Coll M and Mielach FA Choice of cyclophosphamide dose in baboon-to-human liver transplantation. 1993 Lancet pmid:7679768
Kobayashi M et al. HLA-DR matching effect in orthotopic liver transplantation under FK 506. 1993 Transplant. Proc. pmid:7679812
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Murase N et al. Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. 1993 Transplant. Proc. pmid:7679817
Schreier MH et al. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? 1993 Transplant. Proc. pmid:7679818
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Starzl TE FK 506 versus cyclosporine. 1993 Transplant. Proc. pmid:7679820
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Stephens J et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. 1993 Transplant. Proc. pmid:7680144
Bonet H et al. Survival of patients transplanted with alcoholic hepatitis plus cirrhosis as compared with those with cirrhosis alone. 1993 Transplant. Proc. pmid:7680145
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Shibata T et al. Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart? 1993 Transplant. Proc. pmid:7680147
Todo S et al. Intestinal transplantation in humans under FK 506. 1993 Transplant. Proc. pmid:7680148
Reyes J et al. Nutritional management of intestinal transplant recipients. 1993 Transplant. Proc. pmid:7680149
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
McCauley J The nephrotoxicity of FK506 as compared with cyclosporine. 1993 Curr. Opin. Nephrol. Hypertens. pmid:7532089
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Krentz AJ et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. 1993 Diabetes pmid:7694879
Yem AW et al. An active FK506-binding domain of 17,000 daltons is isolated following limited proteolysis of chicken thymus hsp56. 1993 Biochemistry pmid:7504525
Manev H et al. Macrolide antibiotics protect neurons in culture against the N-methyl-D-aspartate (NMDA) receptor-mediated toxicity of glutamate. 1993 Brain Res. pmid:7504570
Takahara S et al. [Blood level monitoring of FK506 on kidney transplant recipients]. 1993 Nippon Hinyokika Gakkai Zasshi pmid:7504758
Lieberman I et al. Synergy between tetrandrine and FK506 in prevention of diabetes in BB rats. 1993 Life Sci. pmid:7504774
Xu RX et al. 1H, 13C, and 15N assignments and secondary structure of the FK506 binding protein when bound to ascomycin. 1993 Biopolymers pmid:7682113
Müller MK et al. [Pathophysiologic concepts and protective possibilities in experimental pancreatic lesions]. 1993 Z Gastroenterol pmid:7504856
Tanaka N et al. Regulation of liver regeneration by interleukin-2 and its inhibitors: cyclosporine A and FK 506. 1993 Int. J. Immunopharmacol. pmid:7682200
Panis Y and Valleur P [Small intestine transplantation. Experimental and clinical results]. 1993 Ann Chir pmid:7504899
Bruserud O and Pawelec G Cyclosporine A and FK506 show similar immunosuppressive effects on long-term in vitro T-cell proliferation. 1993 Int. J. Immunopharmacol. pmid:7682202
Tsai M et al. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. 1993 Eur. J. Immunol. pmid:7504992
Winkler M et al. Anaemia associated with FK 506 immunosuppression. 1993 Lancet pmid:7682273
Hendrickson BA et al. Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. 1993 Gene pmid:7505249
Lundemose AG et al. Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection. 1993 Mol. Microbiol. pmid:7682281
Wiesner RH et al. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. 1993 Transplant. Proc. pmid:7682352
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Frank B et al. Neurotoxicity of FK 506 in liver transplant recipients. 1993 Transplant. Proc. pmid:7682355
Klintmalm GB et al. Rejection: FK 506 for rescue or maintenance. 1993 Transplant. Proc. pmid:7682356
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Fernandes JB et al. Comparative investigation of the effects of the immunosuppressants cyclosporine A, cyclosporine G, and FK-506 on platelet activation. 1993 Cell. Mol. Biol. Res. pmid:7507391
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
McDiarmid SV et al. FK506 conversion for intractable rejection of the liver allograft. 1993 Transpl. Int. pmid:7507675
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Tokunaga Y et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. 1993 Transpl. Int. pmid:7507676
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Winkler M et al. Conversion from cyclosporin to FK 506 after liver transplantation. 1993 Transpl. Int. pmid:7507677
David M et al. [Changes in cervix cytology in women with liver transplants treated with immunosuppressive therapy]. 1993 Zentralbl Gynakol pmid:7692689
Wallemacq PE and Reding R FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. 1993 Clin. Chem. pmid:7693372
Nakamura T et al. Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. 1993 EMBO J. pmid:7693452
Higa A et al. Attenuation of epithelial injury in acute experimental colitis by immunomodulators. 1993 Eur. J. Pharmacol. pmid:7693488
Schmitt J et al. Cloning and expression of a mouse cDNA encoding p59, an immunophilin that associates with the glucocorticoid receptor. 1993 Gene pmid:7693550
Yatscoff RW et al. Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro. 1993 Clin. Biochem. pmid:7507804
Lemster B et al. FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions. 1993 Ann. N. Y. Acad. Sci. pmid:7509134
Tamura K et al. Inhibitory effect of FK 506 on autoimmune thyroid disease in the PVG rat. 1993 Ann. N. Y. Acad. Sci. pmid:7509135
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Ochiai T et al. Combination of immunosuppressive drugs for organ transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509136
Wiederrecht G et al. The mechanism of action of FK-506 and cyclosporin A. 1993 Ann. N. Y. Acad. Sci. pmid:7509138
Morikawa K et al. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. 1993 Antimicrob. Agents Chemother. pmid:7509146
Schwaninger M et al. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line. 1993 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7509460
Mukai H et al. FKBP12-FK506 complex inhibits phosphatase activity of two mammalian isoforms of calcineurin irrespective of their substrates or activation mechanisms. 1993 J. Biochem. pmid:7683641
Takeda Y et al. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. 1993 J. Cardiovasc. Pharmacol. pmid:7509973
Jachez B et al. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. 1993 Anticancer Drugs pmid:7683935
Shapiro R et al. FK 506 interaction with danazol. 1993 Lancet pmid:7684106
Becker JW et al. FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. 1993 J. Biol. Chem. pmid:7684380
Dickey JB et al. Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. 1993 Cornea pmid:7684663
Francavilla A et al. Hepatic regeneration and growth factors. 1993 J Surg Oncol Suppl pmid:7684910
Connelly PR et al. Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. 1993 Biochemistry pmid:7684925
Wallemacq PE et al. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. 1993 Clin. Chem. pmid:7684956
Mochizuki M et al. A clinical trial of FK506 in refractory uveitis. 1993 Am. J. Ophthalmol. pmid:7685147
Hibbins M et al. Inhibition of PHA induced mononuclear cell proliferation by FK506 in combination with cyclosporine, methylprednisolone, 6-mercaptopurine and mycophenolic acid. 1993 Transpl. Immunol. pmid:7521736
Thomson AW et al. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. 1993 Transpl. Immunol. pmid:7521738
Matsuura T et al. Organ-specific unresponsiveness induced by intrathymic injection of donor bone marrow cells and a short course of immunosuppression in the rat heart transplantation model. 1993 Transpl. Immunol. pmid:7521742
Calne RY et al. Intestinal transplant for recurring mesenteric desmoid tumour. 1993 Lancet pmid:7686241
Langer A et al. Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. 1993 Am. J. Pathol. pmid:7686346
Fujisawa T et al. Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation. 1993 Surg. Today pmid:7686416
Ueno M et al. [Immunosuppressive effect in combination therapy of cyclosporine A, FK506 and 15-deoxyspergualin on a pancreatic islet xenotransplantation]. 1993 Nihon Geka Gakkai Zasshi pmid:7686615
Thomson AW et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. 1993 Springer Semin. Immunopathol. pmid:7686690
Koga T et al. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. 1993 Chest pmid:7686837
Nishi M et al. Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. 1993 Invest. Ophthalmol. Vis. Sci. pmid:7686893
Nishizawa S et al. Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. 1993 Neurosurgery pmid:7687044
Warty V et al. FK506 measurement: comparison of different analytical methods. 1993 Ther Drug Monit pmid:7687389
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Shaefer MS et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. 1993 Transplantation pmid:7689264
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Odocha O et al. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689269
McCauley J et al. Renal transplantation under FK 506 in African-Americans: early experience. 1993 Transplant. Proc. pmid:7689270
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
McMaster P and Buist L FK 506 in transplantation. 1993 Transplant. Proc. pmid:7689275
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Cetinkale O et al. The use of FK506 and skin allografting for the treatment of severe burns in an animal model. 1993 Br J Plast Surg pmid:7690295
Hacker J and Fischer G Immunophilins: structure-function relationship and possible role in microbial pathogenicity. 1993 Mol. Microbiol. pmid:7526121
Hom JT and Estridge T FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. 1993 Clin. Immunol. Immunopathol. pmid:7690315
Olivera DL et al. Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. 1993 Clin. Immunol. Immunopathol. pmid:7690317
Whitington PF et al. Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. 1993 Lancet pmid:7690444
Takahashi H and Iizuka H Neither cyclosporin A nor FK506 affects adenylate cyclase responses of fetal rat keratinizing epidermal cells (FRSK cells) at concentrations that inhibit thymidine incorporation. 1993 J. Dermatol. Sci. pmid:7511000
Zuany-Amorim C et al. Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. 1993 Br. J. Pharmacol. pmid:7694762
Hirasé Y et al. Transplantation of long-term cryopreserved allocutaneous tissue by skin graft or microsurgical anastomosis: experimental studies in the rat. 1993 Plast. Reconstr. Surg. pmid:7679796